Bilateral Pulmonary Langerhans’s Cell Histiocytosis is Surgical Challenge in Children: A Case Report

Tutku Soyer1 Gülyüzkel1 Özlem Boybeyi Türer1 Kübra Çakmakkaya2 Sinan Yavuz3
Bilgehan Yalçın4 Diclehan Orhan5 Ebru Yalçın6 Deniz Doğru6 Benan Bayrakçısı Nural Kiper6
Canan Akyüz4

1 Department of Pediatric Surgery, Hacettepe University, Faculty of Medicine, Ankara, Turkey
2 Department of Pediatrics, Hacettepe University, Faculty of Medicine, Ankara, Turkey
3 Department of Pediatric Intensive Care, Hacettepe University, Faculty of Medicine, Ankara, Turkey
4 Department of Pediatric Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey
5 Department of Pediatric Pathology, Hacettepe University, Faculty of Medicine, Ankara, Turkey
6 Department of Pediatric Pulmonology, Hacettepe University, Faculty of Medicine, Ankara, Turkey

Address for correspondence Tutku Soyer, MD, Department of Pediatric Surgery, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey (e-mail: soyer.tutku@gmail.com).

Abstract

Background Pulmonary Langerhans’s cell histiocytosis (PLCH) is a rare cause of interstitial lung disease in children and more than half of the cases are bilateral. Persistent respiratory distress due to spontaneous pneumothorax (SP) in bilateral PLCH may refractory to conservative treatment and posed a great challenge to surgical modalities. A 3-year-old boy with SP due to bilateral PLCH is presented to discuss the surgical options of recurrent and refractory PLCH cases in children.

Case Report The patient was admitted to the emergency department with severe respiratory distress and SP. After chest tube insertion, biopsy from neck mass revealed Langerhans’s cell histiocytosis. Chemotherapy including vinblastine and prednisone was initiated. Due to persistent respiratory difficulty and air leaks, talc pleurodesis and thoracoscopic bullae excision with pleural decortication were performed. Two months after the admission, due to nosocomial infection and severe respiratory distress, extracorporeal membranous oxygenation (ECMO) support was initiated. The patient was died of ECMO complications on 24th day of ECMO.

Conclusion Despite the use of chemotherapy and surgical excision of cystic lesions, bilateral PLCH in children may have lethal outcome. Other treatment options including respiratory support with ECMO and lung transplantation should be considered as last resort of treatment alternative in persistent cases.

Keywords
- pulmonary Langerhans’s cell histiocytosis
- children
- bilateral

© 2019 Georg Thieme Verlag KG Stuttgart · New York
Introduction

Langerhans’s cell histiocytosis (LCH) is a rare disease characterized by abnormal infiltration of certain organs by dendritic cells. Pulmonary involvement in LCH (PLCH) is more common in adults and mostly occurs in smokers. The estimated incidence of LCH is 4 to 9 cases per 1 million in children. Pulmonary involvement as an isolated entity is extremely rare in children and usually can be seen as part of a systemic disease. Pathogenesis of PLCH differs from that of adults where most of the affected adult cases are cigarette smokers. However, no causative relationship has been proven between smoking and pediatric PLCH, passive smoking may considered in the etiology. An uncontrolled immune response to an unknown stimulus or antigen is suggested in the pathogenesis in children.

The clinical findings of PLCH are nonproductive cough and dyspnea. Spontaneous pneumothorax (SP) is resulting from a rupture of subpleural bullae and cystic lesions occur in 10 to 20% of cases. Pleurodesis, cysts excision, and partial or total pleurectomy are common surgical options. Extensive parenchymal destruction due to fibrosis may lead to respiratory failure and end-stage pulmonary disease. There is no consensus on the optimum treatment of bilateral PLCH in children.

A 3-year-old boy with SP due to bilateral PLCH is presented to discuss the surgical options of recurrent and refractory PLCH cases in children.

Case Report

A 3-year-old boy with severe respiratory distress admitted to emergency department. He had pneumothorax at right chest and underwent tube thoracostomy (Fig. 1A). In his past medical history, he has free of symptoms and had no chronic disease. None of the family members had lung disease and none of them were smokers. At admission, his vital signs were within normal limits except high respiratory rate (45/minute). Total blood count, liver, and renal function tests were also unremarkable. On physical examination, a 2 x 1 cm palpable mass was noted at right side of neck. Computed tomography (CT) of chest revealed bilateral air cysts in varying sizes with ground glass appearance (Fig. 1B). Pneumothorax was also detected. The patient underwent biopsy form the neck mass and diagnosed as LCH confined to right salivary gland. The histopathologic features include polymorph nuclear leukocytes and atypical histocytes with oval nucleus with pale granular cytoplasm. Immunohistochemical staining with CD1a (cluster of differentiation 1a) and S100 were positive. Chemotherapy including vinblastine and prednisone was initiated. During follow-up, pneumothorax persisted and another chest tube was inserted on the left side. Since the patient was unresponsive to medical treatment 2 weeks after admission, chemical pleurodesis with talc (2 cc) was performed. The pleurodesis was performed through tube thoracostomy. No intrapleural analgesics were used. The tube was clamped for 1 hour and unclamped at the end of procedure. During the clamped period, patients recommended to rotate on each side for 10 minutes. At the end of 10 days follow-up, patient developed bilateral pneumothorax with subcutaneous emphysema despite tube thoracostomy. Thoracoscopic bullae excision with pleural decortication was performed 10 days after talc pleurodesis (Fig. 2). Histopathological evaluation of pleural biopsies obtained by thoracoscopy revealed inflammation and foreign bodies (talc). No lung biopsy was sampled.

New Insights and the Importance for the Pediatric Surgeon

Despite the use of chemotherapy and surgical excision of cystic lesions, bilateral pulmonary Langerhans’s cell histiocytosis in children may have lethal outcome. Other treatment options including respiratory support with extracorporeal membranous oxygenation and lung transplantation should be considered in persistent cases.
Bilateral Pulmonary Langerhans’s Cell Histiocytosis

Soyer et al.

during bullae excision. After surgical excision of subpleural bullae, the patient was symptom free for only 1 week and after developed respiratory insufficiency. Although total pleurectomy was considered for the patient, due to nosocomial pulmonary infection and severe respiratory distress, mechanical ventilation was initiated. Despite high-frequency ventilation, the oxygenation was inadequate and higher pressures are required. Five weeks after the bullae excision, extracorporeal membranous oxygenation (ECMO) support is initiated with vein-venous catheterization via internal jugular vein. At the 24th day of ECMO, he developed cranial bleeding and ventilator herniation and died of bleeding complications.

Discussion

Langerhans’s cell histiocytosis (LCH) is a rare disease occurring in 4 to 9 cases per 1 million children. It encopropsis a heterogeneous spectrum of clinical findings and may involve either a single organ or present as multisystem disease. Pulmonary involvement is seen in 25% of all pediatric cases and usually as part of a multiorgan LCH. Isolated PLCH is reported only 1% of pediatric cases. Bilateral PLCH is also extremely rare in children and may have an unpredictable course and lethal outcome. It predominantly affects young adults between the ages 20 and 40 years, and there is no gender predilection. Pediatric PLCH peaks between 1 and 3 years of age. The exact incidence of PLCH in children is unknown because significant numbers of cases are asymptomatic and may resolve spontaneously. Although it constitutes 4 to 5% of all pediatric lung biopsies, histopathologic diagnosis of PLCH is difficult in advanced disease.

The pathogenesis of PLCH in adults is attributed to cigarette smoking and 95% of affected adults are smokers. In children, immune response to an unknown antigen and/or stimulus is suggested as the underlying cause of LCH. PLCH presents with tachypnea, chest pain, dyspnea, cyanosis, chronic, and persistent cough. SP resulting rupture from cystic lesions may occur as initial presentation. Our patient was also admitted to emergency department with SP and dyspnea. The diagnosis of PLCH is characteristically based on the radiologic findings. It may consist of cystic lesions varying in size and frequently involves lower lobes in children. CT typically shows nodular and reticular lesions in early stages of the disease and cystic lesions in advanced disease. CT scan of our patient also suggested advanced PLCH showing cystic lesions with ground glass appearance. The ground glass opacities are very rare radiologic findings of PLCH and correspond to desquamated interstitial pneumonia like changes. According to the stage of disease, different radiologic findings can be seen. Nodular and ground glass appearance also exhibit regression of PLCH, while emphysema and fibrotic changes suggest persistence and progression. Other nodular and interstitial lung diseases should be differentiated from PLCH. The silicosis and sarcoidosis may have similar nodular lesions in chest scans but very rare in children. Also, different from the infectious causes, PLCH has no lymph nodes in perihilar areas.

Children with progressive PLCH can be treated with chemotherapy including vinblastine, prednisone, methotrexate, cyclophosphamide, and etoposide. The clinical response to chemotherapy is unpredictable in children and requires long-term follow-up. Vinblastine and prednisone was the choice of chemotherapy in our patient and partial response was obtained during the medical treatment. The role of passive cigarette smoking in the development of PLCH is controversial in children. However, there is no prospective data suggesting improvement of outcome by stopping smoke exposure; it is highly recommended.

The treatment option of recurrent pneumothoraces is tube thoracotomy in most cases. Other surgical interventions are needed when there is no improvement in respiratory functions after 12-week course of chemotheraphy; persistent pneumothorax due to chest tubes or worsening of CT scan findings during follow-up. The conservative treatment of recurrent pneumothoraces in PLCH usually fails since the underlying lungs are very fragile and tend to collapse easily. The recurrence rate of pneumothorax treated with chest tube is only 58%. Chemical pleurodesis has limited rate of success in the treatment of extensive PLCH and not recommended if there is a possibility of lung transplantation. At the early stages of disease, we used chemical pleurodesis with talc after full extension of lungs with tube thoracostomy. However, talc pleurodesis was failed and did not prevent recurrent pneumothoraces. Abdul Aziz et al reported that mechanical pleurodesis is superior to chemical pleurodesis. It can be performed by either with thoracotomy or thoracoscopic. It is not considered as a contraindication for transplantation. Therefore, thoracoscopic excision of cysts with partial pleurectomy was performed. In extensive PLCH, partial pleurectomy and/or abrasion of pleura may not be sufficient to eradicate persistent pneumothorax. Total pleurectomy is an aggressive surgical alternative that can be used in recurrent pneumothorax. Although better outcomes are reported, it should be the last resort of surgical treatment in children. For our patient, authors discussed to perform bilateral total pleurectomy as last surgical option to avoid recurrence. But, due to nosocomial respiratory infection and need of ventilator support, it was not possible to perform total pleurectomy.

Lung transplantation is a therapeutic option in selected cases with progressive disease. It should be considered when severe pulmonary hypertension exists and not response to vasodilator treatment. Surgical pleurodesis did not preclude...
lung transplantation. ECMO has been shown to be a valid alternative as a bridge for lung transplantation in PLCH.\textsuperscript{15} It was not considered as an alternative treatment in our case because of severe deterioration of the patient.

The prognosis of PLCH is variable and unpredictable in pediatric age group. The poor outcome of the PLCH is related with extremes age, prolonged worse conditions, multiorgan involvement, reduced diffusion capacity, extensive cysts and honeycombing on imaging, recurrent pneumothoraces, pulmonary hypertension, and prolonged treatment.\textsuperscript{16} Death may occur due to pulmonary hypertension and/or severe respiratory insufficiency. Our patient had most of the poor prognostic factors and died due to severe pulmonary insufficiency and ECMO complications.

**Conclusion**

In conclusion, despite the use of chemotherapy and surgical excision of cystic lesions, bilateral PLCH in children may have lethal outcome. Other treatment options including respiratory support with ECMO and lung transplantation should be kept in mind in persistent cases.

**Note**

This case report is presented in the Joint Congress of 36th National Congress of Turkish Association of Pediatric Surgeons and International Pediatric Endosurgery Group (IPEG), Middle East Chapter, October 24 to 27, 2018, Izmir, Turkey.

**Conflict of Interest**

None.

**Acknowledgement**

Authors would like to thank to Professor Alev Özön for her kind contribution to organize a multidisciplinary approach for the patient.

**References**

1. Favara BE, Feller AC, Pauli M, et al; The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Contemporary classification of histiocytic disorders. Med Pediatr Oncol 1997;29(03):157–166
2. Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N Engl J Med 2002;346(07):484–490
3. Alston RD, Tatevossian RG, McNally RJ, Kelsey A, Birch JM, Eden TO. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer 2007;48(05):555–560
4. Suri HS, Yi ES, Nowakowski GS, Vassallo R. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis 2012;7:16
5. Schulze J, Kitz R, Grüttnar HP, Schmidt H, Zielen S. Severe isolated pulmonary Langerhans cell histiocytosis in a 6-year-old girl. Eur J Pediatr 2004;163(06):320–322
6. Braier J, Latella A, Balancini B, Castaños C, Goldberg J. Isolated pulmonary Langerhans cell histiocytosis presenting with recurrent pneumothorax. Pediatr Blood Cancer 2007;48(02):241–244
7. Dauriat G, Mail H, Thabut G, et al. Lung transplantation for pulmonary langerhans’ cell histiocytosis: a multicenter analysis. Transplantation 2006;81(05):746–750
8. Ronceray L, Pötschger U, Janka G, Gadner H, Minkov M; German Society for Pediatric Hematology and Oncology, Langerhans Cell Histiocytosis Study Group. Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome. J Pediatr 2012;161(01):129–33.e1, 3
9. Braier J, Latella A, Balancini B, et al. Outcome in children with pulmonary Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43(07):765–769
10. Al-Trabolsi HA, Alshehri M, Al-Shomrani A, Shabanah M, Al-Barki AA. “Primary” pulmonary Langerhans cell histiocytosis in a two-year-old child: case report and literature review. J Pediatr Hematol Oncol 2006;28(02):79–81
11. Brauner MW, Grenier P, Tijani K, Battesti JP, Valeyre D. Pulmonary Langerhans cell histiocytosis: evolution of lesions on CT scans. Radiology 1997;204(02):497–502
12. Vassallo R, Ryu JH. Pulmonary Langerhans’ cell histiocytosis. Clin Chest Med 2004;25(03):561–571, vii
13. Abdul Aziz DA, Abdul Rahman NA, Tang SF, et al. Total pleurectomy as the surgical treatment for recurrent secondary spontaneous pneumothorax in a child with severe pulmonary Langerhans cells histiocytosis. BMJ Case Rep 2011:2011:bcr0920114734
14. Mendez JL, Nadrous HF, Vassallo R, Decker PA, Ryu JH. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest 2004;125(03):1028–1032
15. Sacco O, Moscatelli A, Conte M, et al. Long-term extracorporeal membrane oxygenation as bridging strategies to lung transplantation in rapidly devastating isolated langerhans cell histiocytosis. Pediatr Blood Cancer 2016;63(05):941–943
16. Bano S, Chaudhary V, Narula MK, et al. Pulmonary Langerhans cell histiocytosis in children: a spectrum of radiologic findings. Eur J Radiol 2014;83(01):47–56